From cellular morphology to molecular and epigenetic anomalies of myelodysplastic syndromes (Q57283873)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30303583%20AND%20SRC:MED&resulttype=core&format=json

27 April 2020

title

From cellular morphology to molecular and epigenetic anomalies of myelodysplastic syndromes (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30303583%20AND%20SRC:MED&resulttype=core&format=json

27 April 2020

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30303583%20AND%20SRC:MED&resulttype=core&format=json

27 April 2020

Aline Rangel Pozzo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30303583%20AND%20SRC:MED&resulttype=core&format=json

27 April 2020

language of work or name

English

0 references

publication date

18 November 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30303583%20AND%20SRC:MED&resulttype=core&format=json

Genes, Chromosomes and Cancer

27 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30303583%20AND%20SRC:MED&resulttype=core&format=json

27 April 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30303583%20AND%20SRC:MED&resulttype=core&format=json

27 April 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30303583%20AND%20SRC:MED&resulttype=core&format=json

27 April 2020

page(s)

474-483

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30303583%20AND%20SRC:MED&resulttype=core&format=json

Many are called MDS cell lines: one is chosen

27 April 2020

cites work

1 reference

7 January 2021

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications

1 reference

7 January 2021

Myelodysplastic Syndromes

1 reference

7 January 2021

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

1 reference

7 January 2021

The classification of MDS: from FAB to WHO and beyond

1 reference

7 January 2021

Preleukemia: one name, many meanings

1 reference

7 January 2021

1 reference

7 January 2021

1 reference

7 January 2021

Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies

1 reference

7 January 2021

Establishing the incidence of myelodysplastic syndrome

1 reference

7 January 2021

Myelodysplastic syndromes: the complexity of stem-cell diseases

1 reference

7 January 2021

Myelodysplastic syndromes: a view from where the sun rises and where the sun sets

1 reference

7 January 2021

Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes

1 reference

7 January 2021

The WHO classification of MDS does make a difference

1 reference

7 January 2021

Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines.

1 reference

7 January 2021

Profiling Three-Dimensional Nuclear Telomeric Architecture of Myelodysplastic Syndromes and Acute Myeloid Leukemia Defines Patient Subgroups

1 reference

7 January 2021

Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management

1 reference

7 January 2021

Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome

1 reference

7 January 2021

Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

1 reference

7 January 2021

Comparison of bone marrow and hematologic findings in patients with human immunodeficiency virus infection and those with myelodysplastic syndromes and infectious diseases

1 reference

7 January 2021

Prognostic implication and characterization of the blast cell population in the myelodysplastic syndrome

1 reference

7 January 2021

World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

1 reference

7 January 2021

The World Health Organization (WHO) classification of the myeloid neoplasms

1 reference

7 January 2021

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

1 reference

7 January 2021

Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management

1 reference

7 January 2021

Proposals for the classification of the myelodysplastic syndromes

1 reference

7 January 2021

New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients

1 reference

7 January 2021

New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge

1 reference

7 January 2021

Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System

1 reference

7 January 2021

Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.

1 reference

7 January 2021

Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes

1 reference

7 January 2021

Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome

1 reference

7 January 2021

Long-term transfusion independence in del(5q) MDS patients who discontinue lenalidomide

1 reference

7 January 2021

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

1 reference

7 January 2021

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

1 reference

7 January 2021

Persistent malignant stem cells in del(5q) myelodysplasia in remission

1 reference

7 January 2021

Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression

1 reference

7 January 2021

Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities

1 reference

7 January 2021

A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome

1 reference

7 January 2021

Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders

1 reference

7 January 2021

Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse

1 reference

7 January 2021

A critical role for Apc in hematopoietic stem and progenitor cell survival

1 reference

7 January 2021

Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation

1 reference

7 January 2021

Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype

1 reference

7 January 2021

Transcript map and comparative analysis of the 1.5-Mb commonly deleted segment of human 5q31 in malignant myeloid diseases with a del(5q)

1 reference

7 January 2021

Cytogenetic and genetic pathways in therapy-related acute myeloid leukemia.

1 reference

7 January 2021

Molecular pathophysiology of myelodysplastic syndromes.

1 reference

7 January 2021

Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation

1 reference

7 January 2021

CUX1 is a haploinsufficient tumor suppressor gene on chromosome 7 frequently inactivated in acute myeloid leukemia

1 reference

7 January 2021

CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine

1 reference

7 January 2021

Cytogenetic features in myelodysplastic syndromes

1 reference

7 January 2021

Coalesced Multicentric Analysis of 2,351 Patients With Myelodysplastic Syndromes Indicates an Underestimation of Poor-Risk Cytogenetics of Myelodysplastic Syndromes in the International Prognostic Scoring System

1 reference

7 January 2021

CD34 cells from patients with trisomy 8 myelodysplastic syndrome (MDS) express early apoptotic markers but avoid programmed cell death by up-regulation of antiapoptotic proteins

1 reference

7 January 2021

The leukemia-associated gene MDS1/EVI1 is a new type of GATA-binding transactivator

1 reference

7 January 2021

Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities

1 reference

7 January 2021

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

1 reference

7 January 2021

Rare cytogenetic abnormalities in myelodysplastic syndromes

1 reference

7 January 2021

New data shed light on Y-loss-related pathogenesis in myelodysplastic syndromes

1 reference

7 January 2021

Trisomy 13: prevalence and clinicopathologic correlates of another potentially lenalidomide-sensitive cytogenetic abnormality

1 reference

7 January 2021

Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13.

1 reference

7 January 2021

Molecular Definition of Interstitial Deletions of Chromosome 13 in Leukemic Cells

1 reference

7 January 2021

Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS.

1 reference

7 January 2021

Myeloid Neoplasms with Isolated Isochromosome 17q: a yet to be Defined Entity

1 reference

7 January 2021

Trisomy 11 in myelodysplastic syndromes defines a unique group of disease with aggressive clinicopathologic features

1 reference

7 January 2021

Trisomy 14 in hematologic diseases. Another non-random abnormality within myeloid proliferative disorders

1 reference

7 January 2021

Aberrant DNA methylation is a dominant mechanism in MDS progression to AML.

1 reference

7 January 2021

Epigenetic aspects of MDS and its molecular targeted therapy

1 reference

7 January 2021

Methylation of the p15(INK4B) gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation

1 reference

7 January 2021

MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation

1 reference

7 January 2021

The genetic basis of myelodysplastic syndromes.

1 reference

7 January 2021

Mutations in epigenetic regulators in myelodysplastic syndromes

1 reference

7 January 2021

Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2

1 reference

7 January 2021

Landscape of genetic lesions in 944 patients with myelodysplastic syndromes

1 reference

7 January 2021

Clinical and biological implications of driver mutations in myelodysplastic syndromes

1 reference

7 January 2021

Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases

1 reference

7 January 2021

Enforced differentiation of Dnmt3a-null bone marrow leads to failure with c-Kit mutations driving leukemic transformation

1 reference

7 January 2021

Incidence and Prognostic Influence of DNMT3A Mutations in Acute Myeloid Leukemia

1 reference

7 January 2021

IDH1 Mutation Is an Independent Inferior Prognostic Indicator for Patients with Myelodysplastic Syndromes

1 reference

7 January 2021

Roles of IDH1/2 and TET2 mutations in myeloid disorders.

1 reference

7 January 2021

Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms

1 reference

7 January 2021

IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis.

1 reference

7 January 2021

Clinical effect of point mutations in myelodysplastic syndromes

1 reference

7 January 2021

Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes

1 reference

7 January 2021

Genomic loss of EZH2 leads to epigenetic modifications and overexpression of the HOX gene clusters in myelodysplastic syndrome

1 reference

7 January 2021

Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

1 reference

7 January 2021

Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders

1 reference

7 January 2021

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet

1 reference

7 January 2021

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

1 reference

7 January 2021

Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome

1 reference

7 January 2021

Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma

1 reference

7 January 2021

Hematopoiesis in 3 dimensions: human and murine bone marrow architecture visualized by confocal microscopy

1 reference

7 January 2021

Nuclear remodeling as a mechanism for genomic instability in cancer.

1 reference

7 January 2021

Shelterin: the protein complex that shapes and safeguards human telomeres

1 reference

7 January 2021

The relationship between spontaneous telomere loss and chromosome instability in a human tumor cell line.

1 reference

7 January 2021

DNA amplification by breakage/fusion/bridge cycles initiated by spontaneous telomere loss in a human cancer cell line.

1 reference

7 January 2021

The loss of a single telomere can result in instability of multiple chromosomes in a human tumor cell line

1 reference

7 January 2021

Telomere dysfunction in genome instability syndromes.

1 reference

7 January 2021

The three-dimensional organization of telomeres in the nucleus of mammalian cells

1 reference

7 January 2021

Oncogenic remodeling of the three-dimensional organization of the interphase nucleus: c-Myc induces telomeric aggregates whose formation precedes chromosomal rearrangements.

1 reference

7 January 2021

The significance of telomeric aggregates in the interphase nuclei of tumor cells

1 reference

7 January 2021

Telomeric aggregates and end-to-end chromosomal fusions require myc box II.

1 reference

7 January 2021

Dynamic chromosomal rearrangements in Hodgkin's lymphoma are due to ongoing three-dimensional nuclear remodeling and breakage-bridge-fusion cycles

1 reference

7 January 2021

The 3D nuclear organization of telomeres marks the transition from Hodgkin to Reed-Sternberg cells

1 reference

7 January 2021

Three-dimensional nuclear telomere architecture is associated with differential time to progression and overall survival in glioblastoma patients

1 reference

7 January 2021

In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis.

1 reference

7 January 2021

The myelodysplastic syndromes in 1996: complex stem cell disorders confounded by dual actions of cytokines.

1 reference

7 January 2021

Evidence for involvement of tumor necrosis factor-alpha in apoptotic death of bone marrow cells in myelodysplastic syndromes

1 reference

7 January 2021

Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes

1 reference

7 January 2021

Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies

1 reference

7 January 2021

Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts

1 reference

7 January 2021

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms

1 reference

7 January 2021

Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes

1 reference

7 January 2021

Identifiers

DOI

10.1002/GCC.22689

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30303583%20AND%20SRC:MED&resulttype=core&format=json

27 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30303583%20AND%20SRC:MED&resulttype=core&format=json